Inhibikase Therapeutics (IKT) Interest Coverage Ratio (2020 - 2025)
Inhibikase Therapeutics (IKT) posted quarterly Interest Coverage Ratio of 0.44 for Q4 2025, up 99.85% quarter-over-quarter from 282.66 in Q2 2025.
Inhibikase Therapeutics (IKT) Interest Coverage Ratio (2020 - 2025) Analysis & Trends
Inhibikase Therapeutics (IKT) has reported Interest Coverage Ratio for 6 consecutive years, with 0.44 the latest figure, recorded in Q4 2025.
- In Q4 2025, Interest Coverage Ratio changed N/A year-over-year to 0.44; the TTM figure through Dec 2025 stood at 1.64 (changed N/A YoY), while the FY2025 annual figure was 1.64, down 78.59% from the prior year.
- Interest Coverage Ratio advanced to 0.44 in Q4 2025 per IKT's latest filing, from 282.66 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 273.1 in Q4 2021 and bottomed at 28477.96 in Q3 2021.
- Historically, Interest Coverage Ratio has averaged 2826.65 across 5 years, with a median of 152.87 in 2023.
- On a YoY basis, Interest Coverage Ratio climbed as much as 262.36% in 2021 and fell as far as 29463.13% in 2021.
- Inhibikase Therapeutics' Interest Coverage Ratio stood at 273.1 in 2021, then slumped by 123.51% to 64.2 in 2022, then plunged by 130.15% to 147.76 in 2023, then surged by 74.27% to 38.02 in 2024, then jumped by 98.86% to 0.44 in 2025.
- Business Quant data shows IKT's Interest Coverage Ratio at 0.44 in Q4 2025, 282.66 in Q2 2025, and 7798.08 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Inhibikase Therapeutics | 420.72 Mn | 261.70 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -0.44 |
| Jun 30, 2025 | -282.66 |
| Mar 31, 2025 | -7,798.08 |
| Sep 30, 2024 | -38.02 |
| Jun 30, 2024 | -26.51 |
| Mar 31, 2024 | -261.13 |
| Sep 30, 2023 | -147.76 |
| Jun 30, 2023 | -152.87 |
| Mar 31, 2023 | -94.88 |
| Sep 30, 2022 | -64.20 |
| Mar 31, 2022 | -4,769.37 |
| Dec 31, 2021 | 273.10 |
| Sep 30, 2021 | -28,477.96 |
| Jun 30, 2021 | -336.50 |
| Mar 31, 2021 | -222.54 |
| Dec 31, 2020 | -168.21 |
| Sep 30, 2020 | -96.33 |
| Jun 30, 2020 | -52.08 |
| Mar 31, 2020 | -72.73 |